Energy Infrastructure Content Hub VettaFi Voices On: The Outlook for 2024 By Heather BellDecember 8, 2023
ETF Building Blocks Content Hub Play US Gene Treatment Approval in SBIO By Nick Peters-GoldenDecember 7, 2023
ETF Building Blocks Content Hub Innovation Could Propel Biotechnology Bounce By Todd ShriberOctober 31, 2023
ETF Building Blocks Content Hub 3 Growth-Minded ETFs to Play Fed Rate Pause By Nick Peters-GoldenJune 13, 2023
ETF Building Blocks Content Hub ALPS’ Biotech ETF SBIO Week’s Top Performer By Nick Peters-GoldenApril 24, 2023
ETF Building Blocks Content Hub Biotech ETFs’ Performance Deserves A Look By Nick Peters-GoldenApril 19, 2023
ETF Building Blocks Content Hub Biotech M&A Could Finally Be Ready to Rebound By Tom LydonFebruary 23, 2023
ETF Building Blocks Content Hub Look to SBIO for Biotech Exposure By Elle Caruso FitzgeraldDecember 12, 2022
ETF Building Blocks Content Hub Gene Deal Adds New Dimension to Biotech ETF SBIO By Nick Peters-GoldenNovember 16, 2022
ETF Building Blocks Content Hub SBIO Rallied While Major Indexes Declined Last Week By Elle Caruso FitzgeraldOctober 4, 2022
ETF Building Blocks Content Hub SBIO Outpaced XBI, IBB in Volatile Last Week By Elle Caruso FitzgeraldSeptember 21, 2022
ETF Building Blocks Content Hub SBIO Was ALPS’ Top Performing ETF in August By Elle Caruso FitzgeraldSeptember 1, 2022
ETF Building Blocks Content Hub SBIO Rallies on M&A Announcements By Elle Caruso FitzgeraldAugust 10, 2022
Featured Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal By Max ChenAugust 5, 2022
Featured Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics By Max ChenAugust 4, 2022
ETF Building Blocks Content Hub SBIO Increases on Biotech’s Sustained Rebound By Elle Caruso FitzgeraldJuly 20, 2022
